Send us Fan Mail

Steve Anderson explains why Renue Medical Centre, his specialty hospital in Nuevo Vallarta, puts physical therapy and orthobiologics ahead of surgery. He contrasts that pathway with the surgery-first habit in the United States and Canada, then covers induced pluripotent stem cells, diabetes trials, and the cost of treating cell deficits late. Listeners also hear who pays for longevity care, and why organ replacement is moving faster than most patients think.

Website

See More ChalkTalkJim Episodes

Send us Fan Mail

Drug approval rewards a single patented product proven in large trials.

Dr. Francisco Contreras of Oasis of Hope argues that this model leaves out personalized cell therapies and cheap natural compounds that no company will pay to test.

We discuss why the FDA standard exists and asks whether government-funded studies should fill the gap to fund the evidence for products without a patent. A frank conversation about cancer, drugs, and alternative therapies.

LinkedIn

Company Website

See More ChalkTalkJim Episodes

Send us Fan Mail

Health systems pay to bring patients to their website, then lose them at the search box.

Chris Pace of SearchStax, who was the former Sr. Director of Marketing for Banner Health. He was a SearchStax customer who was so confident in the product, he joined SearchStax.

Chris explains why owned search is the most ignored part of digital access. He shares how a chest pain search once returned a blog post, how a moved MyChart login drove up calls to one call center, and what search data reveals about unmet demand.

LinkedIn

Company Website

See More ChalkTalkJim Episodes